Moleculin Biotech (MBRX) Current Assets (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Current Assets of $9.7 million for Q4 2025, up 86.48% year-over-year from $5.2 million in Q4 2024, and up 22.84% quarter-over-quarter from $7.9 million in Q3 2025.
Moleculin Biotech (MBRX) Current Assets (2015 - 2026) Analysis & Trends
Moleculin Biotech's Current Assets history runs 11 years deep, the most recent figure standing at $9.7 million for Q4 2025.
- In Q4 2025, Current Assets rose 86.48% year-over-year to $9.7 million; the TTM figure through Dec 2025 stood at $9.7 million (up 86.48% YoY), while the FY2025 annual figure was $9.7 million, up 86.48% from the prior year.
- Current Assets for Q4 2025 stood at $9.7 million, up from $7.9 million in the prior quarter.
- The five-year high for Current Assets was $88.0 million in Q1 2021, with the low at $5.2 million in Q4 2024.
- The 5-year median for Current Assets is $31.5 million (2023), against an average of $38.1 million.
- The sharpest annual moves came in 2021 and 2024: Current Assets soared 538.42% in 2021, then slumped 80.23% in 2024.
- Moleculin Biotech's Current Assets stood at $72.5 million in 2021, then tumbled by 37.11% to $45.6 million in 2022, then plunged by 42.38% to $26.3 million in 2023, then plunged by 80.23% to $5.2 million in 2024, then soared by 86.48% to $9.7 million in 2025.
- Business Quant data shows MBRX's Current Assets at $9.7 million in Q4 2025, $7.9 million in Q3 2025, and $9.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | 8.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.72 Mn |
| Dec 31, 2025 | 9.69 Mn |
| Sep 30, 2025 | 7.89 Mn |
| Jun 30, 2025 | 9.08 Mn |
| Mar 31, 2025 | 9.34 Mn |
| Dec 31, 2024 | 5.19 Mn |
| Sep 30, 2024 | 11.61 Mn |
| Jun 30, 2024 | 13.73 Mn |
| Mar 31, 2024 | 18.96 Mn |
| Dec 31, 2023 | 26.27 Mn |
| Sep 30, 2023 | 27.60 Mn |
| Jun 30, 2023 | 35.38 Mn |
| Mar 31, 2023 | 39.29 Mn |
| Dec 31, 2022 | 45.60 Mn |
| Sep 30, 2022 | 53.49 Mn |
| Jun 30, 2022 | 61.32 Mn |
| Mar 31, 2022 | 67.26 Mn |
| Dec 31, 2021 | 72.50 Mn |
| Sep 30, 2021 | 77.07 Mn |
| Jun 30, 2021 | 81.84 Mn |